Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

The lightbulb moment behind a potential antiviral breakthrough 

Published

on

Testing antiviral vaccines in the lab

An unexpected observation by a University of Queensland (UQ) researcher could lead to a new treatment for deadly infectious diseases including Covid‑19, pneumonia in infants and children, or viral infections caused by Ebola and hantavirus.  

UQ’s Australian Institute for Bioengineering and Nanotechnology neuroscientist and biochemist Dr Merja Joensuu said the idea came while working on unrelated research. “We were studying how certain processes work inside the human brain when I noticed a disruption in a pathway that numerous human viruses rely on to spread from one cell to the next. That was the lightbulb moment. We realised that if we interfere with that pathway, we might be able to stop viruses from forming properly.”  

With her collaborator Professor Giuseppe Balistreri from the University of Helsinki, the research team searched for a compound that could inhibit this pathway and found one currently being trialled as a cancer treatment.  

Human enzyme N‑myristoyltransferase 1 (NMT1), which helps direct where proteins are located and how they function within human cells, was the compound’s target. 

“Viruses can’t reproduce on their own, so they hijack human cells to make new copies,” Professor Balistreri said. “This drug disrupts how the cell functions, causing new viruses to be assembled incorrectly. The virus doesn’t know this and keeps making and releasing less-effective versions of itself, which would give the immune system time to clean up the infection.” 

Drug testing 

In laboratory studies, the researchers tested the drug against a range of viruses in cell cultures including SARS‑CoV‑2 (which causes Covid‑19), respiratory syncytial virus, a major cause of pneumonia in infants, and vesicular stomatitis virus, which causes disease in cattle, horses and occasionally humans. They found infection levels dropped by about half after one day, and by up to 90% after two days.  

 “The reduction is quite striking,” Dr Joensuu said. “The study also suggests this strategy could potentially work on viruses with high mortality rates and long incubation time like Ebola and hantavirus. All viruses rely on exploiting host cell processes to replicate and spread. Because we are interfering with the host cell instead of directly targeting the virus, there is less chance of it mutating and building resistance to the drug.”  

Researchers emphasised the drug is not yet approved for this use, with further studies needed to confirm safety and effectiveness, but Dr Joensuu said it showed a lot of promise. “You can imagine that this could be a very effective antiviral, for example with treating respiratory conditions, used in the form of a nasal spray or an inhaler,” she said. 

The post The lightbulb moment behind a potential antiviral breakthrough  appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read